RS Investment Management Co. LLC cut its stake in shares of Amedisys Inc. (NASDAQ:AMED) by 0.1% during the second quarter, Holdings Channel reports. The institutional investor owned 801,563 shares of the company’s stock after selling 519 shares during the period. RS Investment Management Co. LLC’s holdings in Amedisys were worth $40,463,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of AMED. Renaissance Technologies LLC increased its stake in Amedisys by 81.1% in the first quarter. Renaissance Technologies LLC now owns 630,901 shares of the company’s stock valued at $30,498,000 after buying an additional 282,600 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Amedisys by 53.8% in the first quarter. Goldman Sachs Group Inc. now owns 61,584 shares of the company’s stock valued at $2,977,000 after buying an additional 21,535 shares in the last quarter. State Street Corp increased its stake in Amedisys by 6.3% in the first quarter. State Street Corp now owns 686,983 shares of the company’s stock valued at $33,211,000 after buying an additional 40,819 shares in the last quarter. M&T Bank Corp purchased a new stake in Amedisys during the first quarter valued at about $367,000. Finally, Acrospire Investment Management LLC purchased a new stake in Amedisys during the first quarter valued at about $108,000. Hedge funds and other institutional investors own 91.45% of the company’s stock.

Amedisys Inc. (NASDAQ:AMED) traded up 1.04% during mid-day trading on Wednesday, hitting $49.63. The stock had a trading volume of 171,367 shares. The firm has a market cap of $1.66 billion, a PE ratio of 43.42 and a beta of 1.05. The company has a 50-day moving average of $48.60 and a 200-day moving average of $49.35. Amedisys Inc. has a 12-month low of $31.16 and a 12-month high of $55.16.

Amedisys (NASDAQ:AMED) last announced its earnings results on Tuesday, August 2nd. The company reported $0.42 earnings per share for the quarter, meeting the consensus estimate of $0.42. The company earned $360 million during the quarter, compared to the consensus estimate of $353.07 million. Amedisys had a return on equity of 12.17% and a net margin of 2.78%. The company’s revenue was up 14.8% on a year-over-year basis. During the same period last year, the firm earned $0.43 earnings per share. Analysts expect that Amedisys Inc. will post $1.69 earnings per share for the current year.

AMED has been the subject of several analyst reports. Mizuho cut Amedisys from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $57.00 to $55.00 in a research note on Wednesday, August 3rd. Zacks Investment Research cut Amedisys from a “hold” rating to a “sell” rating in a research note on Monday, July 11th. Jefferies Group reissued a “buy” rating and set a $59.00 target price on shares of Amedisys in a research note on Wednesday, May 25th. Stephens initiated coverage on Amedisys in a research note on Thursday, June 16th. They set an “equal weight” rating and a $55.00 target price for the company. Finally, Wells Fargo & Co. reissued a “buy” rating on shares of Amedisys in a research note on Sunday, September 11th. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $51.75.

About Amedisys

Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.

5 Day Chart for NASDAQ:AMED

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc. (NASDAQ:AMED).

Receive News & Ratings for Amedisys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.